- Home
- NUAI vs CANF Comparison
NUAI vs CANF Comparison
Compare NUAI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUAI
- CANF
- Stock Information
- Founded
- NUAI N/A
- CANF 1994
- Country
- NUAI United States
- CANF Israel
- Employees
- NUAI N/A
- CANF N/A
- Industry
- NUAI Oil & Gas Production
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NUAI Energy
- CANF Health Care
- Exchange
- NUAI Nasdaq
- CANF Nasdaq
- Market Cap
- NUAI 11.3M
- CANF 9.6M
- IPO Year
- NUAI N/A
- CANF N/A
- Fundamental
- Price
- NUAI $0.40
- CANF $0.67
- Analyst Decision
- NUAI
- CANF Strong Buy
- Analyst Count
- NUAI 0
- CANF 2
- Target Price
- NUAI N/A
- CANF $14.50
- AVG Volume (30 Days)
- NUAI 7.1M
- CANF 135.8K
- Earning Date
- NUAI 08-14-2025
- CANF 08-26-2025
- Dividend Yield
- NUAI N/A
- CANF N/A
- EPS Growth
- NUAI N/A
- CANF N/A
- EPS
- NUAI N/A
- CANF N/A
- Revenue
- NUAI $718,761.00
- CANF $560,000.00
- Revenue This Year
- NUAI N/A
- CANF $461.72
- Revenue Next Year
- NUAI N/A
- CANF N/A
- P/E Ratio
- NUAI N/A
- CANF N/A
- Revenue Growth
- NUAI 14.80
- CANF N/A
- 52 Week Low
- NUAI $0.32
- CANF $0.63
- 52 Week High
- NUAI $12.29
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- NUAI N/A
- CANF 41.47
- Support Level
- NUAI N/A
- CANF $0.64
- Resistance Level
- NUAI N/A
- CANF $0.68
- Average True Range (ATR)
- NUAI 0.00
- CANF 0.02
- MACD
- NUAI 0.00
- CANF 0.01
- Stochastic Oscillator
- NUAI 0.00
- CANF 91.25
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).